Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that a member of management discharging managerial responsibilities has purchased shares in the company.
The company’s Chief Operating Officer, Maj Hedtjärn has reported that she has bought 8,000 shares in December 2021. This brings her total shareholding up to 24,000 shares.
Persons under an obligation to report are persons discharging managerial responsibilities, as well as persons closely associated with them.
For further information please contact:
Mads Kronborg, Head of External Communication
Phone: +45 6051 4955
The information was provided by the contact person above for publication on February 4, 2022, at 08.30 CET.
Scandion Oncology A/S, the Cancer Drug Resistance Company, is a clinical phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.
Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market and can be reached at email@example.com or +46 (0) 40 200 250.